Cerus Corp. (NASDAQ:CERS) shares traded down 2.2% during mid-day trading on Thursday . The company traded as low as $6.23 and last traded at $6.26, with a volume of 478,327 shares trading hands. The stock had previously closed at $6.40.

A number of research analysts recently issued reports on the company. FBR & Co reiterated a “buy” rating on shares of Cerus Corp. in a report on Wednesday, May 4th. Cantor Fitzgerald reiterated a “buy” rating and issued a $8.00 target price on shares of Cerus Corp. in a report on Thursday, March 10th. BTIG Research reiterated a “buy” rating on shares of Cerus Corp. in a report on Monday, March 14th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $9.00 target price on shares of Cerus Corp. in a report on Wednesday, March 16th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Cerus Corp. presently has an average rating of “Buy” and an average price target of $8.90.

The firm’s market cap is $646.88 million. The firm’s 50 day moving average price is $5.88 and its 200-day moving average price is $5.79.

Cerus Corp. (NASDAQ:CERS) last issued its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. During the same period in the previous year, the business earned ($0.17) EPS. The business earned $7.60 million during the quarter, compared to the consensus estimate of $8.29 million. The business’s revenue was down 1.3% compared to the same quarter last year. On average, equities analysts predict that Cerus Corp. will post ($0.65) EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in CERS. Wells Fargo & Company MN increased its stake in Cerus Corp. by 25.9% in the fourth quarter. Wells Fargo & Company MN now owns 4,901,666 shares of the company’s stock worth $30,979,000 after buying an additional 1,007,430 shares during the last quarter. Stephens Inc. AR increased its stake in Cerus Corp. by 11.3% in the fourth quarter. Stephens Inc. AR now owns 1,112,665 shares of the company’s stock worth $7,032,000 after buying an additional 113,238 shares during the last quarter. EAM Investors LLC purchased a new stake in Cerus Corp. during the fourth quarter worth approximately $1,139,000. California State Teachers Retirement System increased its stake in Cerus Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 176,709 shares of the company’s stock worth $1,117,000 after buying an additional 3,126 shares during the last quarter. Finally, Rail Splitter Capital Management LLC increased its stake in Cerus Corp. by 19.0% in the fourth quarter. Rail Splitter Capital Management LLC now owns 832,722 shares of the company’s stock worth $5,263,000 after buying an additional 132,970 shares during the last quarter.

Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.